1. Home
  2. Clinical Topics
  3. FDA approves first biosimilar for certain breast, stomach cancers
Clinical TopicsDrugs and DevicesOncologyWeb Exclusives
fda breast stomach cancer

FDA approves first biosimilar for certain breast, stomach cancers

Share

On Dec. 1, the U.S. Food and Drug Administration (FDA) approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). This is the first biosimilar approved in the U.S. for the treatment of breast or stomach cancer. 

Read more via Fda.gov.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts